Published in Chem Biol on January 01, 2005
TLR-independent control of innate immunity in Caenorhabditis elegans by the TIR domain adaptor protein TIR-1, an ortholog of human SARM. Nat Immunol (2004) 4.11
Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat Chem Biol (2010) 2.15
Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol (2002) 1.76
Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proc Natl Acad Sci U S A (2012) 1.57
Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators through structural and fluorescence anisotropy studies. J Biol Chem (2004) 1.44
Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res (2008) 1.43
Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns. Proc Natl Acad Sci U S A (2004) 1.38
Discovery of thieno[2,3-c]pyridines as potent COT inhibitors. Bioorg Med Chem Lett (2008) 1.30
Rapid sensing of circulating ghrelin by hypothalamic appetite-modifying neurons. Proc Natl Acad Sci U S A (2013) 1.27
Probing the existence of G protein-coupled receptor dimers by positive and negative ligand-dependent cooperative binding. Mol Pharmacol (2006) 1.20
Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther (2002) 1.16
Distinct roles of metabotropic glutamate receptor dimerization in agonist activation and G-protein coupling. Proc Natl Acad Sci U S A (2012) 1.12
Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor. Proc Natl Acad Sci U S A (2012) 1.12
Systematic investigation of benzodithiophene- and diketopyrrolopyrrole-based low-bandgap polymers designed for single junction and tandem polymer solar cells. J Am Chem Soc (2012) 1.11
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem (2007) 1.02
The opening of the SPP1 bacteriophage tail, a prevalent mechanism in Gram-positive-infecting siphophages. J Biol Chem (2011) 1.01
Crystal structure of the coiled-coil dimerization motif of geminin: structural and functional insights on DNA replication regulation. J Mol Biol (2004) 1.01
High constitutive activity is an intrinsic feature of ghrelin receptor protein: a study with a functional monomeric GHS-R1a receptor reconstituted in lipid discs. J Biol Chem (2011) 0.99
Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. J Am Soc Nephrol (2009) 0.99
BIGH3 (TGFBI) Arg124 mutations influence the amyloid conversion of related peptides in vitro. Eur J Biochem (2002) 0.97
Homogeneous time-resolved fluorescence-based assay to screen for ligands targeting the growth hormone secretagogue receptor type 1a. Anal Biochem (2010) 0.97
Discovery of a highly active ligand of human pregnane x receptor: a case study from pharmacophore modeling and virtual screening to "in vivo" biological activity. Mol Pharmacol (2007) 0.95
Presence of functional oxytocin receptors in cultured human myoblasts. J Clin Endocrinol Metab (2002) 0.94
The constitutively active V2 receptor mutants conferring NSIAD are weakly sensitive to agonist and antagonist regulation. PLoS One (2009) 0.94
Leukotriene BLT2 receptor monomers activate the G(i2) GTP-binding protein more efficiently than dimers. J Biol Chem (2009) 0.93
Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A. J Med Chem (2006) 0.92
e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design. Bioinformatics (2012) 0.92
Fluorescent ligands to investigate GPCR binding properties and oligomerization. Biochem Soc Trans (2013) 0.90
Structural basis for the interaction between focal adhesion kinase and CD4. J Mol Biol (2007) 0.89
Activation of the ghrelin receptor is described by a privileged collective motion: a model for constitutive and agonist-induced activation of a sub-class A G-protein coupled receptor (GPCR). J Mol Biol (2009) 0.88
New advances in production and functional folding of G-protein-coupled receptors. Trends Biotechnol (2011) 0.87
Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem (2002) 0.87
Differential coupling of the vasopressin V1b receptor through compartmentalization within the plasma membrane. Mol Pharmacol (2008) 0.85
Techniques: Oxidative cross-linking as an emergent tool for the analysis of receptor-mediated signalling events. Trends Pharmacol Sci (2005) 0.85
Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays. J Med Chem (2012) 0.85
Molecular detection of Coxiella burnetii and Neospora caninum in equine aborted foetuses and neonates. Prev Vet Med (2011) 0.85
FATP1 inhibits 11-cis retinol formation via interaction with the visual cycle retinoid isomerase RPE65 and lecithin:retinol acyltransferase. J Biol Chem (2010) 0.84
Identification of the binding sites of the SR49059 nonpeptide antagonist into the V1a vasopressin receptor using sulfydryl-reactive ligands and cysteine mutants as chemical sensors. J Biol Chem (2003) 0.84
Heterodimerization with Its splice variant blocks the ghrelin receptor 1a in a non-signaling conformation: a study with a purified heterodimer assembled into lipid discs. J Biol Chem (2013) 0.84
2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization. Bioorg Med Chem Lett (2009) 0.83
Herpesviruses in respiratory liquids of horses: putative implication in airway inflammation and association with cytological features. Vet Microbiol (2009) 0.82
High-level expression and purification of the human bradykinin B(2) receptor in a tetracycline-inducible stable HEK293S cell line. Protein Expr Purif (2007) 0.81
Time resolved FRET strategy with fluorescent ligands to analyze receptor interactions in native tissues: application to GPCR oligomerization. Methods Mol Biol (2011) 0.80
Vpr expression abolishes the capacity of HIV-1 infected cells to repair uracilated DNA. Nucleic Acids Res (2013) 0.80
Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban. J Pept Sci (2005) 0.80
Engineering a G protein-coupled receptor for structural studies: stabilization of the BLT1 receptor ground state. Protein Sci (2009) 0.79
Long-lasting airway inflammation associated with equid herpesvirus-2 in experimentally challenged horses. Vet J (2013) 0.79
Identification of equid herpesvirus-5 in respiratory liquids: a retrospective study of 785 samples taken in 2006-2007. Vet J (2008) 0.79
Immiscible solvents enabled nanostructure formation for efficient polymer photovoltaic cells. Nanotechnology (2014) 0.78
The two NK-1 binding sites correspond to distinct, independent, and non-interconvertible receptor conformational states as confirmed by plasmon-waveguide resonance spectroscopy. Biochemistry (2006) 0.78
Amphipols in G protein-coupled receptor pharmacology: what are they good for? J Membr Biol (2014) 0.78
Expression, purification and NMR characterization of the cyclic recombinant form of the third intracellular loop of the vasopressin type 2 receptor. Protein Expr Purif (2011) 0.78
Introduction of a cis-prolyl mimic in position 7 of the peptide hormone oxytocin does not result in antagonistic activity. J Med Chem (2005) 0.78
Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. J Pharmacol Exp Ther (2003) 0.78
Expression of human vasopressin and oxytocin receptors in Escherichia coli. Prog Brain Res (2002) 0.77
Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance. Oncotarget (2014) 0.77
Identification by MALDI-TOF mass spectrometry of 17 alpha-bromoacetamidopropylestradiol covalent attachment sites on estrogen receptor alpha. Biochemistry (2002) 0.77
Design of benzophenone-containing photoactivatable linear vasopressin antagonists: pharmacological and photoreactive properties. J Med Chem (2005) 0.77
Experimental model of equine alveolar macrophage stimulation with TLR ligands. Vet Immunol Immunopathol (2013) 0.77
The multifunctional protein GC1q-R interacts specifically with the i3 loop arginine cluster of the vasopressin V2 receptor. Regul Pept (2008) 0.77
Functional role of the conserved proline in helix 6 of the human bradykinin B2 receptor. Biochem Biophys Res Commun (2007) 0.77
Molecular detection of Theileria equi and Babesia caballi in the bone marrow of asymptomatic horses. Vet Parasitol (2010) 0.77
Design and synthesis of novel imidazo[1,2-a]quinoxalines as PDE4 inhibitors. Bioorg Med Chem (2004) 0.77
Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist. J Med Chem (2010) 0.76
Differential interactions of estrogens and antiestrogens at the 17 beta-hydroxyl or counterpart hydroxyl with histidine 524 of the human estrogen receptor alpha. Biochemistry (2002) 0.76
Red fluorescent turn-on ligands for imaging and quantifying G protein-coupled receptors in living cells. Chembiochem (2014) 0.76
Structure of the third intracellular loop of the vasopressin V2 receptor and conformational changes upon binding to gC1qR. J Mol Biol (2009) 0.76
Solid-phase organic tagging resins for labeling biomolecules by 1,3-dipolar cycloaddition: application to the synthesis of a fluorescent non-peptidic vasopressin receptor ligand. Chemistry (2008) 0.76
How ligands and signalling proteins affect G-protein-coupled receptors' conformational landscape. Biochem Soc Trans (2013) 0.76
The backbone model of the Arabis mosaic virus reveals new insights into functional domains of Nepovirus capsid. J Struct Biol (2013) 0.76
Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists. J Med Chem (2005) 0.76
[Handling G-protein-coupled receptors: expression, purification and in vitro stabilization]. Med Sci (Paris) (2012) 0.75
Correction: Effects of Moderate Amounts of Barley in Late Pregnancy on Growth, Glucose Metabolism and Osteoarticular Status of Pre-Weaning Horses. PLoS One (2016) 0.75
Structure-activity relationships of Bak derived peptides: affinity and specificity modulations by amino acid replacement. Eur J Med Chem (2007) 0.75
Protein-ligand structure guided by backbone and side-chain proton chemical shift perturbations. J Biomol NMR (2014) 0.75
N-1H-benzimidazol-5-ylbenzenesulfonamide derivatives as potent hPXR agonists. Bioorg Med Chem (2008) 0.75
[Pharmacological chaperones: a potential therapeutic treatment for conformational diseases]. Med Sci (Paris) (2010) 0.75
High performance low band gap polymer solar cells with a non-conventional acceptor. Chem Commun (Camb) (2012) 0.75